{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:36Z","timestamp":1761895956747},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T00:00:00Z","timestamp":1414368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with chronic myeloid leukemia in chronic phase who achieve early molecular response (<jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content>; generally defined as <jats:italic><jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content><\/jats:italic>\u2010<jats:italic><jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content><\/jats:italic> \u2264\u00a010% on the International Scale at 3 or 6\u00a0months) have improved outcomes. However, there is no consensus on whether <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> failure at 3\u00a0months requires a change in therapy, and the value of the 6\u2010month time point remains under debate. Some patients who do not achieve <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> at 3\u00a0months achieve significant decreases in <jats:italic><jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content><\/jats:italic> levels by 6\u00a0months, whereas others have progressive disease. For patients who do not achieve <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> at either time point, the risk of disease progression is higher both between 3 and 6\u00a0months and over the longer term, underlining the therapeutic relevance of the 3\u2010 to 6\u2010month time period. For patients with <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> failure at 3\u00a0months, although there is currently no consensus on whether to switch therapy or wait until the 6\u2010month assessment, some patients may benefit from an early change in treatment. This review synthesizes key clinical data demonstrating improved outcomes associated with the achievement of <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> and discusses the relevance of the 3\u2010 and 6\u2010month time points on survival and the risk of disease progression. Several potential clinical situations are also presented to explore when a change in therapy may be considered.<\/jats:p>","DOI":"10.1111\/ejh.12453","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T11:13:16Z","timestamp":1411643596000},"page":"103-112","source":"Crossref","is-referenced-by-count":7,"title":["Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3\u2010 and 6\u2010month time points"],"prefix":"10.1111","volume":"95","author":[{"given":"Simona","family":"Lapusan","sequence":"first","affiliation":[{"name":"Saint Antoine Hospital Pierre and Marie Curie University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology SA Pathology and School of Medicine University of Adelaide Adelaide SA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Vanderbilt School of Medicine Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Saint Antoine Hospital Pierre and Marie Curie University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.745525"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.69.69","article-title":"Assessment of early molecular response as a predictor of long\u2010term clinical outcomes in the phase 3 BELA study","volume":"120","author":"Brummendorf TH","year":"2012","journal-title":"Blood"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466037"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.181"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_10_16_1","article-title":"Early molecular response predicts achievement of undetectable BCR\u2010ABL in patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with nilotinib: 3\u2010year follow\u2010up of ENESTcmr","volume":"99","author":"Branford S","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091272"},{"key":"e_1_2_10_18_1","unstructured":"ISRCTN Register.SPIRIT 3: to evaluate the most effective way to use imatinib nilotinib and ponatinib in the treatment of chronic myeloid leukaemia.http:\/\/www.controlled-trials.com\/ISRCTN60655195\/. Accessed September 20 2013."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11520"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_22_1","article-title":"ENESTnd 5\u2010year follow\u2010up: continued benefit of frontline nilotinib (NIL) compared with\u00a0imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP)","volume":"99","author":"Hughes TP","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_10_23_1","article-title":"Four\u2010year (yr) follow\u2010up of patients (pts) with newly diagnosed chronic myeloid leukemia In chronic phase (CML\u2010CP) receiving dasatinib or imatinib: efficacy based on early response","volume":"122","author":"Cortes JE","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_10_26_1","article-title":"EPIC: a phase 3 trial of ponatinib vs imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CP\u2010CML)","volume":"99","author":"Chuah C","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728"},{"key":"e_1_2_10_28_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. v3.2014."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5217"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12187"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23707"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.253.253","article-title":"Optimizing early prediction of outcome in CML using the exact decline of BCR\u2010ABL transcript levels within 3\u00a0months of imatinib treatment as a prognostic marker","volume":"122","author":"Hanfstein B","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293977"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566323"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.116"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.812034"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12453","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.12453","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:05:22Z","timestamp":1696302322000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,27]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/ejh.12453"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12453","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,27]]}}}